MDxHealth is trading at $0.18, down 11.23%, after suspending full-year 2026 revenue guidance.
- On October 15, the company reported preliminary Q3 revenue of about $22.7 million and suspended guidance of $110–115 million.
- It cited unexpected sales-force turnover following the discontinuation of Resolve mdx.
- On October 19, BTIG downgraded the stock to Neutral from Buy, citing the Q3 miss and guidance suspension.